The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial

Sophia Zoungas; John Chalmers; Andre-Pascal Kengne; Avinesh Pillai; Laurent Billot; Bastiaan E De Galan; Michel Marre; Bruce Neal; Stephen Harrap; Neil Poulter; Anushka Patel

doi:10.1016/j.diabres.2010.05.012

The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial

Sophia Zoungas, John Chalmers, Andre-Pascal Kengne, Avinesh Pillai, Laurent Billot, Bastiaan E De Galan, Michel Marre, Bruce Neal, Stephen Harrap, Neil Poulter, Anushka Patel

School of Public Health and Preventive Medicine

Research output: Contribution to journal › Article › Research › peer-review

39 Citations (Scopus)

Abstract

The aim of these analyses was to examine the efficacy of the intensive gliclazide MR-based glucose lowering regimen used in the ADVANCE trial in lowering the level of glycated haemoglobin (HbA1c). All 11,140 randomised patients were included in analyses of treatment efficacy. Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments. At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5 at baseline to 6.5 in those on intensive glucose control and to 7.3 in those on standard glucose control. With intensive glucose lowering greater proportions achieved HbA1c levels of <or =7.0 , <or =6.5 and <or =6.0 . With intensive glucose lowering substantial reductions in HbA1c were observed across subgroups defined by baseline age, sex, duration of diabetes, BMI, HbA1c or treatment regimen (p

Original language	English
Pages (from-to)	126 - 133
Number of pages	8
Journal	Diabetes Research and Clinical Practice
Volume	89
Issue number	2
DOIs	https://doi.org/10.1016/j.diabres.2010.05.012
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diabres.2010.05.012

Cite this

Zoungas, S., Chalmers, J., Kengne, A.-P., Pillai, A., Billot, L., De Galan, B. E., Marre, M., Neal, B., Harrap, S., Poulter, N., & Patel, A. (2010). The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Research and Clinical Practice, 89(2), 126 - 133. https://doi.org/10.1016/j.diabres.2010.05.012

@article{604a499b62b540c2a30ec5f01b6319c1,

title = "The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial",

abstract = "The aim of these analyses was to examine the efficacy of the intensive gliclazide MR-based glucose lowering regimen used in the ADVANCE trial in lowering the level of glycated haemoglobin (HbA1c). All 11,140 randomised patients were included in analyses of treatment efficacy. Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments. At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5 at baseline to 6.5 in those on intensive glucose control and to 7.3 in those on standard glucose control. With intensive glucose lowering greater proportions achieved HbA1c levels of ",

author = "Sophia Zoungas and John Chalmers and Andre-Pascal Kengne and Avinesh Pillai and Laurent Billot and \{De Galan\}, \{Bastiaan E\} and Michel Marre and Bruce Neal and Stephen Harrap and Neil Poulter and Anushka Patel",

year = "2010",

doi = "10.1016/j.diabres.2010.05.012",

language = "English",

volume = "89",

pages = "126 -- 133",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier",

number = "2",

}

Zoungas, S, Chalmers, J, Kengne, A-P, Pillai, A, Billot, L, De Galan, BE, Marre, M, Neal, B, Harrap, S, Poulter, N & Patel, A 2010, 'The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial', Diabetes Research and Clinical Practice, vol. 89, no. 2, pp. 126 - 133. https://doi.org/10.1016/j.diabres.2010.05.012

TY - JOUR

T1 - The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial

AU - Zoungas, Sophia

AU - Chalmers, John

AU - Kengne, Andre-Pascal

AU - Pillai, Avinesh

AU - Billot, Laurent

AU - De Galan, Bastiaan E

AU - Marre, Michel

AU - Neal, Bruce

AU - Harrap, Stephen

AU - Poulter, Neil

AU - Patel, Anushka

PY - 2010

Y1 - 2010

N2 - The aim of these analyses was to examine the efficacy of the intensive gliclazide MR-based glucose lowering regimen used in the ADVANCE trial in lowering the level of glycated haemoglobin (HbA1c). All 11,140 randomised patients were included in analyses of treatment efficacy. Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments. At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5 at baseline to 6.5 in those on intensive glucose control and to 7.3 in those on standard glucose control. With intensive glucose lowering greater proportions achieved HbA1c levels of

AB - The aim of these analyses was to examine the efficacy of the intensive gliclazide MR-based glucose lowering regimen used in the ADVANCE trial in lowering the level of glycated haemoglobin (HbA1c). All 11,140 randomised patients were included in analyses of treatment efficacy. Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments. At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5 at baseline to 6.5 in those on intensive glucose control and to 7.3 in those on standard glucose control. With intensive glucose lowering greater proportions achieved HbA1c levels of

UR - http://www.ncbi.nlm.nih.gov/pubmed/20541825

UR - https://www.scopus.com/pages/publications/77955094828

U2 - 10.1016/j.diabres.2010.05.012

DO - 10.1016/j.diabres.2010.05.012

M3 - Article

SN - 0168-8227

VL - 89

SP - 126

EP - 133

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - 2

ER -

The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial

Abstract

UN SDGs

Access to Document

Other files and links

Cite this